Navigation Links
Orcrist Bio Inc. Files with European Competent Authority for a Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750

CALGARY, Feb. 9 /PRNewswire/ - Orcrist Bio Inc. (ORC) a biotech company developing stem cell-mobilizing pharmaceuticals, announced today that it has filed with the European Competent Authority in Seville, Spain, a Phase I, open-label, single-ascending-dose, safety study of HYC750 in healthy male volunteers. The goal of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics (induction of hematopoiesis) of HYC750, a patent-protected formulation of hyaluronan. ORC utilized the regulatory expertise and experience of Kinesis Pharma BV (Breda, Netherlands) to develop the clinical trial submission. The planned study is to be conducted by InPEC BV (Breda, Netherlands) at their clinical trial site in Malaga, Spain.

Dr. Thomas Ichim, Chairman of ORC's Scientific Advisory Board commented "HYC750 possesses a very favourable pharmacological and pharmaceutical profile and is an excellent candidate for aggressive and rapid clinical development."

"Filing the requisite regulatory documentation with the European authorities to initiate our Phase I clinical trial was a major accomplishment for our company and represents Orcrist's most important milestone thus far," said Dr. Brett Schönekess, President and CEO of Orcrist. "We are thrilled with the expertise and professionalism provided by both Kinesis and InPEC, and are very excited to see the HYC750 clinical program move forward. Our clinical goal is to confirm the safety profile of HYC750 and to see a clear illustration of its stem cell mobilization properties, which would support its future development as a treatment for chemotherapy-related blood cell depletion."

"We are very honored to be chosen by Orcrist to coordinate and perform their Phase I study with HYC750 and we look forward to the future initiation of the trial" commented Dr. Ronald van der Geest, Chief Business Officer of InPEC BV. "Orcrist, Kinesis, and InPEC have worked as a team on this project, and I believe a very strong clinical trial application has been submitted."

About Orcrist Bio Inc.

Orcrist Bio Inc. is a biotechnology company dedicated to developing and commercializing promising therapeutics for areas in which a clear market opportunity exists. ORC's lead program revolves around HYC750, a novel stem cell mobilizer compound that promotes the egress of stem cells and other blood cells from the bone marrow into the blood, from which they can be harvested and applied toward treating chemotherapy-related white blood cell depletion. Orcrist is actively looking to add to its pipeline exploring the innate properties of HYC750 and its effects on stem cells, as well as through in-licensing opportunities of other products with clear market potential. ORC is located in Calgary, Alberta. The company is financed by its founders and by private investors.

About Kinesis Pharma BV

Kinesis Pharma BV is an independent, privately owned company based in The Netherlands. Kinesis aims to facilitate a fast and high quality drug development process in close collaboration with the preclinical and clinical R&D departments of pharmaceutical and biotech companies through consultancy and contract research services. Currently, Kinesis employs about 55 people, many of them with extensive industrial and/or regulatory experience.

About InPEC BV

InPEC BV is a clinical CRO that focuses on the execution of Phase I and IIa clinical trials. Its professional and experienced team, and state of the art facilities, embedded within the care of a private hospital with an ICU unit on the same floor, guarantee maximum safety for the full range of clinical pharmacology studies. Electronic data processing procedures are in place to enable high-quality and efficient data processing on-site. InPEC's head office is located in the Netherlands. Clinical facilities are located in Malaga, Spain.

SOURCE Orcrist Bio Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Tigris Pharmaceuticals Files IND Application for GGTI-2418
2. Panda Ethanols Hereford, Texas Subsidiary Files Voluntary Chapter 11
3. Stem Cell Innovations, Inc., Files New Patent Application
4. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
5. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
6. 3SBio Inc. Files for SFDA Approval of NuLeusin
7. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
8. Sangui BioTech International, Inc. Files Remaining Reports
9. VentriPoint Diagnostics Files Management Discussion and Analysis, Unaudited Financial Results for 2Q 2008
10. China-Biotics, Inc. Files Application for Nasdaq Listing
11. Terumo Cardiovascular Systems Files Patent Infringement Complaint Against Maquet Affiliates
Post Your Comments:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... will join the faculty of the University of North Carolina Kenan-Flagler Business ... strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology:
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... ... ... ...
Breaking Biology News(10 mins):